CytoDyn raises $25M in convertible debt deal to fund its license applications and coronavirus trials

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the group has gone through a second non-dilutive convertible debt offering with an institutional investor, delivering $25 million of immediately available capital for the company’s license applications and coronavirus (COVID-19) trials.

What’s more, Pourhassan also commented on Pfizer and Eli Lily’s efforts to develop vaccines, and how this impacts CytoDyn. He also updated investors on the status of the group’s ongoing coronavirus-focused clinical trials.


All the Admin Templates You Could Ask For.

2M+ items from the worlds largest marketplace for Admin Templates, Themes & Design Assets. Whether that's what you need, or you're just after a few Stock Photos - all of it can be found here at Envato Market.

Related Articles

Back to top button